Table 1 Baseline characteristics of the study population

Population

(N = 24,732)

(N = 13,137)

(N = 4850)

(N = 4486)

(N = 2259)

Event counts

357 (1.5%)

139 (1.1%)

77 (1.5%)

104 (2.2%)

37 (1.7%)

Follow-up time, Median [IQR]

8.97 [6.85, 10.28]

9.11 [8.77, 23.34]

8.80 [5.92, 8.95]

9.40 [9.14, 9.73]

3.01 [2.95, 3.10]

Age at baseline, yr

60.5 (10.3)

54.0 (5.72)

72.1 (5.51)

60.3 (9.57)

73.5 (2.84)

Gender

 Female

14,067 (56.9%)

7433 (56.6%)

2950 (60.8%)

2398 (53.5%)

1286 (56.9%)

 Male

10,665 (43.1%)

5704 (43.4%)

1900 (39.2%)

2088 (46.5%)

973 (43.1%)

Race

 Black

6134 (24.8%)

3256 (24.8%)

768 (15.8%)

1192 (26.6%)

918 (40.6%)

 White

17,075 (69.0%)

9881 (75.2%)

4050 (83.5%)

1803 (40.2%)

1341 (59.4%)

 Other

1523 (6.2%)

0 (0%)

32 (0.7%)

1491 (33.2%)

0 (0%)

Smoking status

 Current

4635 (18.7%)

3281 (25.0%)

589 (12.1%)

554 (12.3%)

211 (9.3%)

 Former

8751 (35.4%)

4183 (31.8%)

1937 (39.9%)

1646 (36.7%)

985 (43.6%)

 Never

11,346 (45.9%)

5673 (43.2%)

2324 (47.9%)

2286 (51.0%)

1063 (47.1%)

BMI

27.5 (5.09)

27.6 (5.30)

26.6 (4.10)

28.3 (5.37)

27.4 (4.80)

Fasting glucose (mg/dL), Median [IQR]

97.3 [90.0, 106.9]

99.0 [93.0, 107.0]

101.0 [94.0, 111.0]

89.0 [82.0, 98.0]

94.0 [87.0, 104.0]

Systolic blood pressure (mmHg)

126 (20.8)

121 (18.3)

140 (20.6)

125 (20.4)

135 (20.5)

Diastolic blood pressure (mmHg)

72.6 (11.1)

73.6 (11.0)

71.0 (11.5)

71.9 (10.1)

71.3 (11.6)

LDL (mg/dL)

131 (37.4)

137 (39.1)

130 (35.4)

117 (31.3)

123 (33.7)

HDL (mg/dL)

52.8 (16.5)

52.1 (17.0)

55.2 (15.7)

51.2 (14.9)

55.1 (16.8)

Medication use

 Antihypertensive medication

8178 (33.1%)

3415 (26.0%)

2106 (43.4%)

1523 (34.0%)

1134 (50.2%)

 Lipid-lowering drugs

1332 (5.4%)

148 (1.1%)

221 (4.6%)

716 (16.0%)

247 (10.9%)

 Oral Antidiabetics

1118 (4.5%)

371 (2.8%)

259 (5.3%)

329 (7.3%)

159 (7.0%)

 Insulin

480 (1.9%)

233 (1.8%)

97 (2.0%)

64 (1.4%)

86 (3.8%)